hs-10370
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 6, 2022 (NCT05367778)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- GTPase KRasANTAGONIST
KRAS
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06963502 | Phase 1 | May 30, 2025 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT06594874 | Phase 1 | Oct 31, 2024 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
| NCT05367778 | Phase 1/Phase 2 (Phase 2) | May 6, 2022 | Huazhong University of Science and Technology, Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiangsu Hansoh Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 2 | 2022 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1